粒细胞集落刺激因子联合聚乙二醇干扰素α-2b、利巴韦林治疗中性粒细胞绝对值减少丙肝肝硬化代偿期患者的临床观察

TL;DRAbstract

Objective To evaluate the efficacy and safety of Granulocyte colony-stimulating factor (G-CSF) combined with PegIFNα-2b and Ribavirin in patients with hepatitis C-related compensated cirrhosis with neutrophil count less than 1.00×10^9/L. Methods Twenty-four patients with hepatitis C-related compensated cirrhosis with neutropenia were given PegIFNα-2b weekly according to bodyweight in doses of 80μg (60 kg) or 50μg (＜ 60 kg), Ribavirin 300 mg tid, and G-CSF (200μg) 1 day before and after each dose of PegIFNα-2b. The course of treatment was 24 weeks and a follow-up of 24 weeks. Results Eight patients dropped off due to poor compliance (7 patients) and severe eruption (1 patient). Sixteen patients finished treatment and follow-up. Only 1 case occurred mild sternal pain, and decompensation of liver function or severe infecion was not observed. The neutrophil count immediately increased after treated with G-CSF; the average neutrophil count of the seventh day every week during treatment was

Chat with Paper

AI Agents for this Paper